Stay updated with breaking news from Global Impression. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
QTORIN™ rapamycin has potential to become first approved therapy and standard of care for Microcystic Lymphatic Malformations in U.S.; significant commercial opportunity based on an estimated more than 30,000 individuals
ATLANTA, July 17, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on...
Disc Medicine, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic... | June 9, 2023
Portfolio company Disc Medicine presents positive initial data from Phase 2 BEACON trial at EHA
Posters presented at the SLEEP 2023 conference showed that transition between medications was easy but 1 medication felt more effective to patients.